Phorum.com.gr

The world's first aerosolized inhalable adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) is progressing well toward obtaining emergency-use approval, and it is expected to be in wide use soon thereafter with proven safety, more robust immune responses, and better effects as a booster, the Global Times learned from the vaccine developer and an industry insider on Wednesday.

If the inhalable Ad5-nCoV is approved for emergency use, it would be the world's first vaccine to achieve triple immunity - humoral, cellular and mucosal - Tao Lina, a Shanghai-based vaccine industry insider, told the Global Times on Wednesday.

The inhalable vaccine can stimulate an immune response in the mucous membranes of a person's respiratory tract. This makes it less painful and more accessible, especially for children and vulnerable people, experts said, as it avoids regional pain and swelling.

What's more, the inhaled form requires only one-fifth of the dosage of an injected one, which preserves more doses and relieves production pressure, according to experts.